Compare MRCC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCC | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 430.2M |
| IPO Year | 2012 | 2020 |
| Metric | MRCC | INBX |
|---|---|---|
| Price | $6.71 | $80.18 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 102.5K | ★ 236.0K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | ★ 15.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $10.81 |
| 52 Week High | $8.85 | $94.47 |
| Indicator | MRCC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 51.68 |
| Support Level | $6.65 | $79.00 |
| Resistance Level | $6.80 | $94.47 |
| Average True Range (ATR) | 0.14 | 6.11 |
| MACD | 0.06 | -1.56 |
| Stochastic Oscillator | 81.30 | 12.77 |
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.